Eli Lilly and Company (LLY)
Lilly appoints insider as finance chief amid rising investments to boost capacity
U.S. drugmaker Eli Lilly on Monday said it has appointed insider Lucas Montarce as its new chief financial officer, effective immediately, months after former CFO Anat Ashkenazi stepped down to join Google parent Alphabet.
Beyond Mounjaro and Zepbound: 6 Other Drugs That Could Be Blockbusters for Eli Lilly
Eli Lilly has three likely blockbuster drugs that are relatively new to the market. Its pipeline features three other late-stage candidates with blockbuster potential.
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Merck & Co., Inc. NYSE: MRK is one of the largest pharmaceutical firms in the world. The firm ranks fourth behind giants like Eli Lilly NYSE: LLY and Novo Nordisk NYSE: NVO, with a market capitalization of $294 billion.
Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals
Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.
Stock Of The Day: Here's Why Weight-Loss Drug Maker Eli Lilly Has Reversed
When stocks rally, they tend to run into resistance if they reach a price level that had been resistance before. And sometimes, after hitting it they reverse and head lower.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Health Rounds: Next generation Lilly weight-loss drug shows added heart, liver benefits
Eli Lilly's experimental next generation weight-loss drug mimics three hormones instead of just one or two and continues to show promising clinical trial results for additional health benefits, the company said.
This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest Problem
Eli Lilly's weight loss drugs are bringing in billions of dollars in revenue, and their performance even prompted the company to increase its annual revenue guidance. But one thing has limited the revenue potential of these drugs.
Healthy Returns: Eli Lilly could soon become the first $1 trillion health-care stock
Eli Lilly could be on its way to topping $1 trillion in market value. Meanwhile, Abbott launches its first over-the-counter continuous glucose monitor in U.S.
Eli Lilly and Company (LLY) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Eli Lilly and Company (NYSE:LLY ) Morgan Stanley 22nd Annual Global Healthcare Conference Call September 5, 2024 7:45 AM ET Company Participants Jacob Van Naarden - Executive Vice President & President of Lilly Oncology Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right. Good morning, everybody.
Eli Lilly's weekly insulin intensifies race with Novo Nordisk
A pair of late-stage trials found that Eli Lilly's experimental once-weekly insulin can lower blood sugar as effectively as widely used daily insulins, the drugmaker said Thursday, intensifying the company's race with Novo Nordisk to develop longer-acting insulins.
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
As demand soars for weight loss medications, so has the competition. Eli Lilly slashed prices for its hugely successful obesity medication, Zepbound.
